EVベースのリキッドバイオプシー市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

EVベースのリキッドバイオプシー市場は、2023年に4億966万米ドルと評価され、2024年には4億7,312万米ドルに達すると予測され、CAGR 15.89%で成長し、2030年には11億5,080万米ドルに達すると予測されています。

EVベースのリキッドバイオプシー市場は、特に腫瘍学、神経学、感染症などにおいて、体液から細胞外小胞（EV）を分析して疾患に関する知見を得ることに焦点を当てた、医療診断の最先端セグメントです。その必要性は、早期診断と個別化された治療計画に不可欠な、患者の健康状態に対するリアルタイムの洞察を提供する非侵襲的診断ツールに対する需要の高まりに起因しています。その応用範囲は広く、がんの検出、治療効果のモニタリング、新規バイオマーカーの発見などが含まれます。エンドユーザーは主に病院、診断研究所、研究機関などです。市場成長の原動力となっているのは、がん罹患率の上昇と次世代シーケンシング（NGS）技術の進歩であり、高精度で効率的な診断ソリューションへの需要を後押ししています。最新の潜在的機会は、EVベースのリキッドバイオプシーの使用を腫瘍学だけでなく心血管疾患や神経変性疾患にも拡大することにあります。高い感度と特異性を確保する堅牢なプラットフォームを開発し、人工知能と組み合わせることで、診断精度を高めることができます。しかしながら、市場の成長は、先端技術の高コスト、EV分離・解析のための標準化プロトコルの欠如、厳しい規制枠組みによる臨床導入の課題などの制約によって妨げられています。革新的な分野には、分離技術の改善や、より良いデータ解釈のためのバイオインフォマティクスツールの強化が含まれます。研究開発は、分析プロトコルの改良、感度の向上、費用対効果の高いソリューションの開発に重点を置き、採用を拡大することが推奨されます。市場は、急速な技術進歩と、新たな機会を捉えるために研究開発に多額の投資を行っている主要企業間の強い競争を特徴としています。企業は、新市場と新技術を持続的に活用するために、戦略的提携やパートナーシップを優先すべきです。全体として、EVベースのリキッドバイオプシー市場には大きな成長の可能性があるが、成功の鍵は、進化する臨床ニーズに対応するための継続的な技術革新と規制上の課題を克服することにあります。

市場力学：急速に進化するEVベースのリキッドバイオプシー市場の主要市場インサイトを公開

EVベースのリキッドバイオプシー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんの流行と早期介入の必要性
  • 非侵襲的診断方法への嗜好の高まり
• 市場抑制要因
  • EVベースのリキッドバイオプシー技術のコスト高
• 市場機会
  • EVベースのリキッドバイオプシー法の進歩
  • リキッドバイオプシーに対する政府の好意的な承認
• 市場の課題
  • EVベースのリキッドバイオプシー実施における技術的合併症

ポーターのファイブフォース：EVベースのリキッドバイオプシー市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：EVベースのリキッドバイオプシー市場における外部からの影響の把握

外部マクロ環境要因は、EVベースのリキッドバイオプシー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析EVベースのリキッドバイオプシー市場における競合情勢の把握

EVベースのリキッドバイオプシー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスEVベースのリキッドバイオプシー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、EVベースのリキッドバイオプシー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨EVベースのリキッドバイオプシー市場における成功への道筋を描く

EVベースのリキッドバイオプシー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの有病率と早期介入の必要性
    • 非侵襲的診断手順に対する好みの増加
  • 抑制要因
    • EVベースのリキッドバイオプシーテクノロジーの高コスト
  • 機会
    • EVベースのリキッドバイオプシー手順の進歩
    • 液体生検に対する政府の好意的な承認
  • 課題
    • EVベースのリキッドバイオプシーを実行する際の技術的な問題
• 市場セグメンテーション分析
  • タイプ：臨床診断に不可欠な標準化されたアプローチとしてのアッセイキットの台頭
  • エンドユーザー：医薬品開発および個別化医療のための学術調査室におけるEVベースのリキッドバイオプシーの採用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 EVベースのリキッドバイオプシー市場：タイプ別

• アッセイキット
• 機器
• サービス

第7章 EVベースのリキッドバイオプシー市場：用途別

• 早期がん検診
• 再発モニタリング
• 治療法の選択
• 治療モニタリング

第8章 EVベースのリキッドバイオプシー市場：エンドユーザー別

• 学術調査機関
• 臨床検査室
• 製薬・バイオテクノロジー企業

第9章 南北アメリカのEVベースのリキッドバイオプシー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のEVベースのリキッドバイオプシー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのEVベースのリキッドバイオプシー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • クエスト・ダイアグノスティクスがヘイスタック・オンコロジーの買収を完了、高感度MRD液体生検技術をがん診断ポートフォリオに追加
  • Agena BioscienceとnRichDXが液体生検検体の抽出と検出のためのソリューションを開発するための商業提携を発表
  • マーシー・バイオアナリティクス、がんの早期発見のための新しいマーシー・ハロ液体生検プラットフォームの開発に向け、シリーズA資金調達で4,100万米ドルを調達
• 戦略分析と提言

企業一覧

• Abcam PLC
• Agena Bioscience
• Agilent Technologies, Inc.
• ALS Automated Lab Solutions GmbH
• ANGLE PLC
• Bio-Rad Laboratories, Inc
• Bio-Techne Corporation
• BioFluidica
• Biological Dynamics
• Bristol-Myers Squibb
• C.H. Boehringer Sohn AG & Co. KG
• Clinomics Europe Ltd.
• Corning Incorporated
• ExosomeDx
• Horiba Ltd.
• Illumina, Inc.
• Lonza Group Ltd.
• Malvern Panalytical Ltd.
• Mercy BioAnalytics, Inc.
• MoBiTec GmbH by BIOZOL Diagnostica Vertrieb GmbH
• Mursla Bio
• Nanostics Inc.
• PerkinElmer, Inc.
• Qiagen N.V.
• Quest Diagnostics
• System Biosciences, LLC
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. EV-BASED LIQUID BIOPSY MARKET RESEARCH PROCESS
• FIGURE 2. EV-BASED LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EV-BASED LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. EV-BASED LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. EV-BASED LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. EV-BASED LIQUID BIOPSY MARKET DYNAMICS
• TABLE 7. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. CANADA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. INDIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. ITALY EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. POLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. QATAR EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM EV-BASED LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. EV-BASED LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. EV-BASED LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

The EV-Based Liquid Biopsy Market was valued at USD 409.66 million in 2023, expected to reach USD 473.12 million in 2024, and is projected to grow at a CAGR of 15.89%, to USD 1,150.80 million by 2030.

The EV-Based Liquid Biopsy market represents a cutting-edge segment in medical diagnostics, focusing on analyzing extracellular vesicles (EVs) from bodily fluids for disease insights, particularly in oncology, neurology, and infectious diseases. Its necessity stems from the increasing demand for non-invasive diagnostic tools that offer real-time insights into patient health, crucial for early diagnosis and personalized treatment plans. The application scope is broad, encompassing cancer detection, monitoring therapeutic efficacy, and uncovering novel biomarkers. End-users primarily include hospitals, diagnostic laboratories, and research institutions. Market growth is fueled by the rising incidence of cancer and advancements in next-generation sequencing (NGS) technologies, propelling the demand for precise and efficient diagnostic solutions. The latest potential opportunities reside in expanding the use of EV-based liquid biopsy beyond oncology to include cardiovascular and neurodegenerative diseases. Developing robust platforms that ensure high sensitivity and specificity, combined with artificial intelligence, could enhance diagnostic accuracy. However, market growth is stymied by limitations such as high costs of advanced technologies, lack of standardized protocols for EV isolation and analysis, and challenges in clinical adoption due to stringent regulatory frameworks. Innovative areas include improving isolation techniques and enhancing bioinformatics tools for better data interpretation. Research is advised to focus on refining analytical protocols, enhancing sensitivity, and developing cost-effective solutions to broaden adoption. The market is characterized by rapid technological advancements and strong competition among key players investing heavily in R&D to capture emerging opportunities. Businesses should prioritize strategic collaborations and partnerships to leverage new markets and emerging technologies sustainably. Overall, the EV-Based Liquid Biopsy market offers substantial growth potential, but success hinges upon overcoming technological and regulatory challenges while continuously innovating to meet evolving clinical needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving EV-Based Liquid Biopsy Market

The EV-Based Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of cancer and need for early intervention
  • Increasing preference for non-invasive diagnostic procedures
• Market Restraints
  • High cost of EV-based liquid biopsy technologies
• Market Opportunities
  • Advancements in EV-based liquid biopsy procedures
  • Favorable government approvals for liquid biopsy
• Market Challenges
  • Technical complications of performing EV-based liquid biopsy

Porter's Five Forces: A Strategic Tool for Navigating the EV-Based Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the EV-Based Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the EV-Based Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the EV-Based Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the EV-Based Liquid Biopsy Market

A detailed market share analysis in the EV-Based Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the EV-Based Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the EV-Based Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the EV-Based Liquid Biopsy Market

A strategic analysis of the EV-Based Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the EV-Based Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Agena Bioscience, Agilent Technologies, Inc., ALS Automated Lab Solutions GmbH, ANGLE PLC, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, BioFluidica, Biological Dynamics, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Co. KG, Clinomics Europe Ltd., Corning Incorporated, ExosomeDx, Horiba Ltd., Illumina, Inc., Lonza Group Ltd., Malvern Panalytical Ltd., Mercy BioAnalytics, Inc., MoBiTec GmbH by BIOZOL Diagnostica Vertrieb GmbH, Mursla Bio, Nanostics Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics, System Biosciences, LLC, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the EV-Based Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Assay Kits, Instruments, and Services.
• Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.
• Based on End User, market is studied across Academic & Research Institutes, Clinical Laboratories, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cancer and need for early intervention
    • 5.1.1.2. Increasing preference for non-invasive diagnostic procedures
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of EV-based liquid biopsy technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in EV-based liquid biopsy procedures
    • 5.1.3.2. Favorable government approvals for liquid biopsy
  • 5.1.4. Challenges
    • 5.1.4.1. Technical complications of performing EV-based liquid biopsy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rise of assay kits as a standardized approach crucial for clinical diagnostics
  • 5.2.2. End User: Adoption of EV-based liquid biopsy in academic and research laboratories for drug development and personalized medicine
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. EV-Based Liquid Biopsy Market, by Type

• 6.1. Introduction
• 6.2. Assay Kits
• 6.3. Instruments
• 6.4. Services

7. EV-Based Liquid Biopsy Market, by Application

• 7.1. Introduction
• 7.2. Early Cancer Screening
• 7.3. Recurrence Monitoring
• 7.4. Therapy Selection
• 7.5. Treatment Monitoring

8. EV-Based Liquid Biopsy Market, by End User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Clinical Laboratories
• 8.4. Pharmaceutical & Biotechnology Companies

9. Americas EV-Based Liquid Biopsy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific EV-Based Liquid Biopsy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa EV-Based Liquid Biopsy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
  • 12.3.2. Agena Bioscience and nRichDX Announce a Commercial Partnership to Create Solutions for the Extraction and Detection of Liquid Biopsy Analytes
  • 12.3.3. Mercy BioAnalytics Raises USD 41 Million in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy Platform for Early Cancer Detection
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abcam PLC
• 2. Agena Bioscience
• 3. Agilent Technologies, Inc.
• 4. ALS Automated Lab Solutions GmbH
• 5. ANGLE PLC
• 6. Bio-Rad Laboratories, Inc
• 7. Bio-Techne Corporation
• 8. BioFluidica
• 9. Biological Dynamics
• 10. Bristol-Myers Squibb
• 11. C.H. Boehringer Sohn AG & Co. KG
• 12. Clinomics Europe Ltd.
• 13. Corning Incorporated
• 14. ExosomeDx
• 15. Horiba Ltd.
• 16. Illumina, Inc.
• 17. Lonza Group Ltd.
• 18. Malvern Panalytical Ltd.
• 19. Mercy BioAnalytics, Inc.
• 20. MoBiTec GmbH by BIOZOL Diagnostica Vertrieb GmbH
• 21. Mursla Bio
• 22. Nanostics Inc.
• 23. PerkinElmer, Inc.
• 24. Qiagen N.V.
• 25. Quest Diagnostics
• 26. System Biosciences, LLC
• 27. Thermo Fisher Scientific, Inc.